Ryk

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-ZP436 Anti-Ryk (Ab5.5) h(CD28-CD3ζ) CAR, pCDCAR1 Human Ab5.5 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP437 Anti-Ryk (Ab5.5) h(41BB-CD3ζ) CAR, pCDCAR1 Human Ab5.5 Humanized scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP438 Anti-Ryk (CAR-ZP438) h(CD28-CD3ζ) CAR, pCDCAR1 Human CAR-ZP438 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP439 Anti-Ryk (CAR-ZP439) h(41BB-CD3ζ) CAR, pCDCAR1 Human CAR-ZP439 Humanized scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP440 Anti-Ryk (RWD1) h(CD28-CD3ζ) CAR, pCDCAR1 Human RWD1 Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP441 Anti-Ryk (RWD1) h(41BB-CD3ζ) CAR, pCDCAR1 Human RWD1 Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP442 Anti-Ryk (TAB-545CL) h(CD28-CD3ζ) CAR, pCDCAR1 Human TAB-545CL Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP443 Anti-Ryk (TAB-545CL) h(41BB-CD3ζ) CAR, pCDCAR1 Human TAB-545CL Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP444 Anti-Ryk (CBCNR-909) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBCNR-909 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP445 Anti-Ryk (CBCNR-909) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBCNR-909 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP446 Anti-Ryk (CBCNR-908) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBCNR-908 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP447 Anti-Ryk (CBCNR-908) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBCNR-908 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP448 Anti-Ryk (484804) h(CD28-CD3ζ) CAR, pCDCAR1 Human 484804 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP449 Anti-Ryk (484804) h(41BB-CD3ζ) CAR, pCDCAR1 Human 484804 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP450 Anti-Ryk (240CT2.2.4) h(CD28-CD3ζ) CAR, pCDCAR1 Human 240CT2.2.4 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP451 Anti-Ryk (240CT2.2.4) h(41BB-CD3ζ) CAR, pCDCAR1 Human 240CT2.2.4 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP452 Anti-Ryk (1671CT575.42.61) h(CD28-CD3ζ) CAR, pCDCAR1 Human 1671CT575.42.61 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP453 Anti-Ryk (1671CT575.42.61) h(41BB-CD3ζ) CAR, pCDCAR1 Human 1671CT575.42.61 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.